Systemic lupus erythematosus and cardiovascular disease

Area of Science:

• Immunology
• Cardiology
• Rheumatology

Background:

• Atherosclerosis, an inflammatory arterial disease, is the primary cause of cardiovascular disease (CVD).
• Systemic lupus erythematosus (SLE) patients face a substantially elevated risk of CVD, making SLE-related atherosclerosis a critical clinical concern.
• Immune system dysregulation in SLE may offer insights into general CVD mechanisms.

Purpose of the Study:

• To investigate the interplay of traditional and non-traditional risk factors contributing to CVD in SLE patients.
• To explore the potential for heightened atherosclerotic lesion vulnerability in SLE compared to non-SLE atherosclerosis.
• To emphasize the clinical importance of monitoring CVD risk in SLE management.

Main Methods:

• Review and synthesis of existing research on CVD risk factors in SLE.
• Analysis of traditional CVD risk factors (dyslipidemia, hypertension, renal disease) in the context of SLE.
• Examination of non-traditional risk factors, including inflammation and antiphospholipid antibodies (aPL), and their association with CVD in SLE.

Main Results:

• CVD risk in SLE is driven by a combination of traditional and non-traditional factors acting synergistically.
• Non-traditional factors such as inflammation, dyslipidemia (high triglycerides), hypertension, renal disease, antiphospholipid antibodies (aPL), and oxidized low-density lipoprotein (LDL) are linked to CVD in SLE.
• Atherothrombosis is a key mechanism, and pro-inflammatory reactions or prothrombotic factors like aPL may increase atherosclerotic plaque rupture risk in SLE.

Conclusions:

• Premature atherosclerosis may be a feature in SLE, though it might affect specific patient subgroups.
• Comprehensive CVD risk management in SLE requires vigilant monitoring of both traditional and non-traditional risk factors.
• Understanding the unique atherosclerotic profile in SLE is crucial for effective CVD prevention and treatment strategies.